Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New poliovirus vaccines: a molecular approach.

Literature DB >> 6085198

New poliovirus vaccines: a molecular approach.

J W Almond, G Stanway, A J Cann, G D Westrop, D M Evans, M Ferguson, P D Minor, M Spitz, G C Schild.

Abstract

This article summarizes recent work on the determinants of antigenicity in poliovirus type 3 and reports on experiments in progress aimed at understanding the molecular basis of attenuation in Sabin's type 3 vaccines. Ways in which this new information might be used to produce alternative, safe, inexpensive, multivalent vaccines against polio and other enteroviruses are discussed.

Entities: Species

Mesh：

Substances：

Year: 1984 PMID： 6085198 DOI： 10.1016/0264-410x(84)90081-1

Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641

Keyword Cloud
Cited

8 in total

1. Analysis of genetic variability and mapping of point mutations in influenza virus by the RNase A mismatch cleavage method.

Authors: C Lopez-Galindez; J A Lopez; J A Melero; L de la Fuente; C Martinez; J Ortin; M Perucho
Journal: Proc Natl Acad Sci U S A Date: 1988-05 Impact factor: 11.205

8. Development of a Genetically-Engineered, Candidate Polio Vaccine Employing the Self-Assembling Properties of the Tobacco Mosaic Virus Coat Protein.

Authors: Joel R Haynes; Janet Cunningham; Adolph von Seefried; Michael Lennick; Robert T Garvin; Shi-Hsiang Shen
Journal: Biotechnology (N Y) Date: 1986

8 in total

New poliovirus vaccines: a molecular approach.

1. Analysis of genetic variability and mapping of point mutations in influenza virus by the RNase A mismatch cleavage method.

2. Poliomyelitis in North America: the disease is not dead yet.

3. Immunological aspects of the prevention of viral diseases. WHO Workshop.

4. Release of genetically altered viruses into the environment.

5. A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans.

6. Behavior of intertypic recombinants between virulent and attenuated aphthovirus strains in tissue culture and cattle.

7. Identification of two determinants that attenuate vaccine-related type 2 poliovirus.

8. Development of a Genetically-Engineered, Candidate Polio Vaccine Employing the Self-Assembling Properties of the Tobacco Mosaic Virus Coat Protein.